Floatz logo

Anti-Cd70-Car-T Cells

Cervix Cancer

Zhejiang UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Cervix Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3B
Vorinostat
UNICANCER
Phase 2CCC
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
OncoNano Medicine, Inc.
Phase 1/2CCC
Vinorelbine
UNICANCER
Phase 1/2CCC

View all 14 →

Same molecule, other indications

Anti-Cd70-Car-T Cells is also rated in:

Metastatic TumorDormant
CC
Indicative ·
43 / 100
View asset →
Relapsed / Refractory Solid TumorDormant
CC
Indicative ·
43 / 100
View asset →
Cutaneous T-cell Lymphoma (CTCL)Dormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →